Egalet to Present at Investor Conferences this Fall

WAYNE, Pa., Sept. 6, 2017

• BioCentury Future Leaders
  September 8, 2017 at 2:00 p.m.
  Millennium Broadway Hotel & Conference Center in New York, NY
  For more information, visit https://www.biocentury.com/conferences/future-leaders-2017.
  
  
• Cantor Fitzgerald Global Healthcare Conference
  September 25, 2017 at 11:30 a.m.
  InterContinental New York Barclay Hotel in New York, NY
  For more information, visit http://www.meetmax.com/sched/event_43201/~public/conference_home.html.
  
  
• The MicroCap Conference
  October 5, 2017
  The Essex House in New York, NY
  For more information, visit http://microcapconf.com/conferences/new-york-2-2017/.

The investor presentations will be audio webcast live and available for replay at Egalet's website at http://egalet.investorroom.com/eventsandwebcasts.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: OXAYDO^® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX^® (ketorolac tromethamine) Nasal Spray. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of clinical-stage, product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO™ ER, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, including the boxed warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com. 

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet's clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet's ability to obtain and maintain regulatory approval of Egalet's products and  product candidates and any regulatory action involving Egalet's products; Egalet's ability to maintain the intellectual property position of Egalet's products and product candidates; Egalet's ability to identify and reliance upon qualified third parties to manufacture its products; Egalet's ability to service its debt obligations; Egalet's ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet's products; the success of products which compete with Egalet's that are or become available; general market conditions; and other risk factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275

View original content with multimedia:http://www.prnewswire.com/news-releases/egalet-to-present-at-investor-conferences-this-fall-300514027.html